The global cirrhosis-specific oral nutrition market is forecast to increase from USD 278.7 million in 2026 to USD 553.3 million by 2036, expanding at a 7.1% CAGR during the 2026–2036 forecast period, according to Future Market Insights. Growth is being supported by the increasing requirement to meet defined protein and energy intake among cirrhosis patients, particularly those unable to obtain sufficient nutrition through regular meals. The market is also benefiting from growing use of measured oral nutrition products across hospitals, homecare, long-term care, and between-meal nutrition schedules.

 

Get detailed market forecasts, competitive benchmarking, and pricing trends:

https://www.futuremarketinsights.com/reports/sample/rep-gb-35634

 

Regional Segment Leaders

As this is a global cirrhosis-specific oral nutrition market report, the segment analysis reflects demand across product type, etiology, product form, end-user, and sales-channel categories.

  • High-protein high-energy ONS — 37.7% of Product Type revenue in 2026: Combined protein and calorie delivery in a measured serving supports patients whose regular meals do not meet nutritional requirements.
  • MASLD / metabolic — 46.8% of Etiology revenue in 2026: Measured oral nutrition helps manage protein requirements associated with cirrhosis while controlling calorie intake among patients with metabolic conditions.
  • RTD — 49.8% of Product Form revenue in 2026: Ready-to-drink products provide measured servings without mixing or preparation, supporting scheduled between-meal and late-evening consumption.
  • Homecare — 43.7% of End User revenue in 2026: Oral nutrition products are commonly continued after hospital discharge, making regular home availability important for maintaining prescribed nutrition schedules.
  • Hospital pharmacy — 36.3% of Sales Channel revenue in 2026: Hospital pharmacies play a key role in initiating oral nutrition products and supplying the first product before patients transition to homecare.

 

Country-Level Performance

The report profiles five key countries, with a 2.0 percentage-point spread between the highest and lowest forecast CAGR.

  • South Korea | CAGR 7.4% (2026–2036) | Key drivers: Disease-specific cirrhosis guidance includes daily energy and protein targets, late-evening snacks, and BCAA supplementation, supporting structured oral nutrition use.
  • USA | CAGR 6.8% (2026–2036) | Key drivers: Hospital nutrition support is supported by cirrhosis guidance, although the lack of Medicare DMEPOS coverage for an orally administered high-protein nutrition shake may limit purchases after discharge.
  • UK | CAGR 6.5% (2026–2036) | Key drivers: National prescribing routes for nutritional products with recognized medical use support the transition from hospital nutrition plans to homecare.
  • Germany | CAGR 6.2% (2026–2036) | Key drivers: Government review processes for balanced enteral nutrition place emphasis on stated medical purpose, nutrient content, and supporting product evidence.
  • Japan | CAGR 5.4% (2026–2036) | Key drivers: The 2025 dietary reference framework supports nutrition assessment and management, while individual protein and energy planning creates demand for convenient oral formats.

 

Regional Context

Cirrhosis-specific oral nutrition is increasingly moving from hospital-based nutrition support toward scheduled use in homecare and other community settings. Defined protein and energy targets make measured oral nutrition products relevant for patients whose regular food intake remains inadequate.

 

The 2026 KASL guideline recommends 30 to 35 kcal/kg per day and 1.2 to 1.5 g/kg of protein, together with late-evening snacks, creating a clinical framework for structured nutrition intake. This supports demand for high-protein high-energy ONS, BCAA supplements, and measured snack products.

 

Product tolerance remains an important commercial constraint. Poor taste, large serving volumes, and uncomfortable daily use can reduce adherence even when nutrient content is appropriate. Compact, ready-to-use products therefore provide an opportunity to improve convenience through measured servings and preparation-free consumption.

 

The shift toward premium-grade oral nutrition is also supported by energy-dense formulations, BCAA content, compact serving sizes, and RTD formats. However, product qualification remains dependent on nutrient composition, medical purpose, evidence, pharmacy availability, serving schedules, and reimbursement documentation.

 

Competitive Landscape

The cirrhosis-specific oral nutrition market is fragmented, with liver-specific formula suppliers competing alongside broader medical nutrition companies.

  • Liver-Specific and Amino-Acid Specialists: Otsuka Pharmaceutical, Ajinomoto, and Victus provide hepatic formulas or amino-acid-based nutrition solutions.
  • Broad High-Protein ONS Platforms: Abbott, Nestle Health Science, Danone Nutricia, and Fresenius Kabi offer high-protein and high-energy oral nutrition products for different care settings.
  • Concentrated Protein and Institutional Access: Medtrition competes through low-volume concentrated protein products designed for acute, long-term, and community nutrition.

 

Notable developments include Danone's September 2026 inauguration of a French medical nutrition line with annual capacity for nearly 20 million liters of oral supplements. In October 2025, Nutricia introduced savory Fortimel PlantBased Protein options, while Medtrition launched ProSource Cup and ProSource Cup Plant in March 2025, each providing 20 grams of complete protein per cup.

 

Get the Complete Story — Read More About Our Latest Report

https://www.futuremarketinsights.com/reports/cirrhosis-specific-oral-nutrition-market

 

Analyst Perspective

“Cirrhosis patients unable to meet the protein requirement through regular meals are increasingly receiving oral nutrition during discharge planning. Product tolerance and regular availability of prescribed formula in homecare will remain important for the market demand.” — Nandini Roy Choudhury, Principal Consultant, Future Market Insights

 

About Future Market Insights (FMI)

 

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

 

For Press & Corporate Inquiries

Rahul Singh AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales: sales@futuremarketinsights.com
For Media: Rahul.singh@futuremarketinsights.com
For Web: https://www.futuremarketinsights.com/